Cardiogen Reconstitution Calculator

Cardiogen is a synthetic tetrapeptide with the sequence H-Ala-Glu-Asp-Arg-OH, one of the short peptide bioregulators (Thymogen, Vilon, Pinealon, Vesugen, Epitalon, Bronchogen, Cardiogen) developed by the Khavinson group at the S.M. Kirov Military Medical Academy. Preclinical profile: stimulates cytoskeletal and nuclear matrix protein expression (in-vitro), supports myocardium tissue culture growth from young and old rats (in-vitro), normalizes heart rate, arrhythmia, and heart/adrenal/spleen mass in adrenaline-stressed rats (animal), and exerts a tumor-modifying effect on M-1 sarcoma in senescent rats (animal). No human clinical trial data exist.

No. Cardiogen (the peptide) has no FDA or EMA approval and no human RCT data in the literature. Note: CardioGen-82® is a different product entirely, an FDA-approved strontium-82/rubidium-82 generator for cardiac PET perfusion imaging. The peptide and the radiopharmaceutical generator share a name only.

Injectable. The rat efficacy studies used injection, and short free tetrapeptides carrying charged residues (arginine, aspartate) have poor oral absorption (mechanistic). Practitioner protocols use ~1–10 mg SC or IM once daily for 10-day courses (practitioner consensus). No oral clinical data exist for this peptide.

Cardiogen (Ala-Glu-Asp-Arg) is the cardioselective member of the family. Its functional signature is cardiac: restoration of heart rate, rhythm, and organ weight ratios under adrenaline stress, induction of cardiomyocyte-relevant cytoskeletal and nuclear matrix proteins, and support of myocardial tissue culture (animal/in-vitro). Epitalon is positioned mainly for pineal/melatonin and lifespan effects in animal models. Choose Cardiogen when the target is myocardial structure and stress tolerance; choose Epitalon for pineal/longevity applications (practitioner consensus).

Established usage is intermittent: 10-day courses repeated 2–3 times per year (practitioner consensus, following short-peptide bioregulator schedules of the Khavinson school ). Continuous long-term human use is unstudied. Animal data indicate effects in senescent/aged tissue, supporting periodic cycling rather than indefinite administration.

Pregnancy/lactation: avoid, no reproductive-safety data exist for this compound. Active cancer: unstudied in humans. Family-level animal data show decreased tumor incidence in peptide-treated animals and Cardiogen itself showed a tumor-modifying effect on M-1 sarcoma in senescent rats, but direction of effect and human risk remain undefined, use only under specialist supervision (community protocol).

Store lyophilized vials refrigerated at 2–8°C; unopened vials remain stable for months under refrigeration (community protocol). After reconstitution with bacteriostatic water, keep refrigerated and use within 14–30 days (community protocol). For travel, carry unreconstituted powder vials in an insulated pack and reconstitute at destination; do not freeze reconstituted solution (community protocol).